BETOPTIC PILO Drug Patent Profile

When do Betoptic Pilo patents expire, and when can generic versions of Betoptic Pilo launch?

Betoptic Pilo is a drug marketed by Alcon and is included in one NDA.

The generic ingredient in BETOPTIC PILO is betaxolol hydrochloride; pilocarpine hydrochloride. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; pilocarpine hydrochloride profile page.

Summary for BETOPTIC PILO

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for BETOPTIC PILO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon	BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020619-001	Apr 17, 1997		DISCN	No	No

International Patents for BETOPTIC PILO

See the table below for patents covering BETOPTIC PILO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2854418
Mexico	9603060	COMPOSICIONES PARA EL TRATAMIENTO DE GLAUCOMA QUE COMPRENDEN PILOCARPINA Y UN BETA-BLOQUEADOR. (COMPOSITIONS FOR TREATMENT OF GLAUCOMA COMPRISING PILOCARPINE AND A BETA-BLOCKER.)
European Patent Office	0429732	Compositions à libération prolongée à base de résines échangeuses d'ions cationiques et de polymères polycarboxyliques. (Sustained-release compositions containing cation exchange resins and polycarboxylic polymers.)

BETOPTIC PILO Market Analysis and Financial Projection

Last updated: February 9, 2026

What is BETOPTIC PILO?

BETOPTIC PILO is a combination ophthalmic solution used primarily for glaucoma treatment. The product combines betaxolol, a beta-adrenergic blocker, with pilocarpine, a cholinergic agent. The formulation aims to reduce intraocular pressure (IOP) by decreasing aqueous humor production and increasing its drainage. BETOPTIC PILO is marketed internationally, with various regional formulations tailored to different market needs.

What are the core components and their mechanisms?

Betaxolol: Selective for beta-1 adrenergic receptors, lowering IOP by reducing aqueous humor secretion. It penetrates ocular tissues effectively, with a favorable systemic side-effect profile given its selectivity.

Pilocarpine: A muscarinic receptor agonist that enhances aqueous outflow through the trabecular meshwork, directly decreasing IOP, especially useful in cases unresponsive to beta-blockers alone.

How does the product's market position look?

Market status: BETOPTIC PILO has a limited but established presence in certain markets. It competes with monotherapies and fixed-dose combinations focusing on glaucoma management.

Key competitors: Other fixed-dose combination (FDC) eye drops such as timolol + brimonidine, dorzolamide + timolol, and newer prostaglandin analogs like latanoprost.

Market size: The global ophthalmic glaucoma medication market was valued at approximately $6 billion in 2021, with a projected compound annual growth rate (CAGR) of 4-6% through 2030 [1].

Distribution: BETOPTIC PILO primarily found in Europe, Asia, and Latin America, with limited penetration in the U.S. due to regulatory and market preferences.

What are the clinical and regulatory fundamentals?

Clinical efficacy: Proven to decrease IOP effectively when used as part of a combination regimen. The synergistic effect of betaxolol and pilocarpine provides dual mechanisms for patients with elevated IOP.

Safety profile:

• Betaxolol: Generally well-tolerated, with local side effects such as burning or stinging, and systemic effects like bradycardia in sensitive patients.
• Pilocarpine: Potential for miosis, brow ache, and visual disturbances; contraindicated in uveitic glaucoma or patients with pulmonary conditions.

Regulatory approvals: Marketed under various brand names depending on region. In the European Union, it often holds licenses based on similar formulations. In emerging markets, regulatory pathways are more flexible but require local clinical data.

What is the growth outlook and investment scenario?

Growth drivers:

• Increasing global prevalence of glaucoma, projected to reach 111 million by 2040 [2].
• Aging population with higher risk for ocular hypertension.
• Limited pipeline of fixed-dose combinations that offer convenience and improved compliance.

Challenges:

• Competition from prostaglandin analogs and combination therapies with better adherence profiles.
• Patents on certain formulations may have expired, leading to generic competition.
• Regulatory hurdles in certain markets for combination drugs.

Investment potential:

• Niche positioning in markets with limited first-line options.
• Opportunities in emerging markets with expanding healthcare infrastructure.
• Need for reformulation or label expansion for broader indications.

R&D prospects: Development of sustained-release formulations or single-agent options incorporating the active components could expand the market. Clinical trials demonstrating superior efficacy or safety profiles would strengthen the competitive edge.

What are the key risks?

• Emergence of new therapies with improved efficacy and safety.
• Regulatory delays or restrictions, especially under evolving global standards.
• Market shifts toward less invasive, once-daily medications with established long-term safety.

What are the strategic considerations for investors?

• Evaluate regional market share and patent landscape.
• Assess pipeline development efforts targeting better compliance and efficacy.
• Monitor clinical trial results and regulatory news for competing products.
• Consider the impact of generic entry on pricing and margins.

Key Takeaways

• BETOPTIC PILO combines betaxolol and pilocarpine for glaucoma management, leveraging dual mechanisms to lower intraocular pressure.
• It holds a defined niche but faces competition from newer agents and formulations offering improved adherence.
• Market growth aligns with increasing global glaucoma prevalence, especially in aging populations.
• Limited pipeline activity suggests the potential for reformulation or combination expansion to sustain growth.
• Competitive risks include patent expiration, regulatory constraints, and rapid innovation in the ophthalmic space.

FAQs

Q1: How effective is BETOPTIC PILO compared to other glaucoma treatments?
It provides effective IOP reduction via dual mechanisms but may be less convenient than once-daily prostaglandin analogs.

Q2: Are there significant safety concerns?
Systemic and local side effects exist but are manageable. Usage contraindications include certain pulmonary and ocular conditions.

Q3: What is the patent landscape for BETOPTIC PILO?
Patents for the formulation may have expired or be nearing expiration, increasing generic competition.

Q4: Is there a pipeline for reformulating BETOPTIC PILO?
Developments could include sustained-release formats or single-agent combinations; however, current activity is limited.

Q5: Which markets offer the best growth opportunities?
Emerging markets with expanding healthcare infrastructure and increasing glaucoma prevalence offer growth potential, especially where fixed-dose combinations improve compliance.

---

References

[1] MarketsandMarkets. "Ophthalmic Drugs Market," 2021.
[2] Tham, Y.C., et al. "Global prevalence of glaucoma and projections of glaucoma burden through 2040," Ophthalmology, 2014.